Curia New York Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Curia- A partner for the pharma and biotech industries to improve patient outcomes & quality of life.
One of their notable products is METOLAZONE, USP, with a corresponding US DMF Number 11958.
Remarkably, this DMF maintains an Active status since its submission on May 02, 1996, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 01, 2016, and payment made on March 24, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II